Type 1 Diabetes study: Liraglutide Pen Injector vs Saline Injections
Official title The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
ClinicalTrials.gov ID: NCT06976619
What this study is testing
What is Liraglutide Pen Injector?
An investigational once‑daily injectable medicine being studied for type 1 diabetes. It is designed to activate the GLP‑1 receptor to influence insulin and glucagon secretion.
Also referred to as Liraglutide.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if controlling blood sugar and using a GLP‑1 receptor agonist changes the amount of GLP‑1 made inside the pancreas. It also compares these effects between type 1 and type 2 diabetes.
- Who it's for
- Adults who have either type 1 or type 2 diabetes and can give informed consent.
- What's involved
- Participants will receive a GLP‑1 receptor agonist or a placebo while their blood sugar is managed. They will have blood tests and other measurements taken to assess pancreatic hormone levels.
- Time commitment
- The study lasts several weeks, with multiple clinic visits for medication administration, blood draws, and monitoring of blood sugar.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 25 to 70
You may be able to join if
- Type 1 or type 2 diabetes treated with insulin
You likely can't join if
- Age \ 70 years.
- HbA1c \> 10.0%
- For female people: positive pregnancy test at the time of enrollment or study
- History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
- Prior use of GLP-1 receptor agonists in the previous year.
- Active systemic illness or malignancy.
See the full eligibility criteria
- Type 1 or type 2 diabetes treated with insulin
- Age \ 70 years.
- HbA1c \> 10.0%
- For female people: positive pregnancy test at the time of enrollment or study
- History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
- Prior use of GLP-1 receptor agonists in the previous year.
- Active systemic illness or malignancy.
- Symptomatic macrovascular or microvascular disease.
The study team makes the final eligibility decision.
Where it is enrolling
- Rochester, Minnesota, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 25 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Rochester, Minnesota, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.